Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary ...

Johnson & Johnson and Sanofi's vaccine for preventing invasive disease caused by the problem pathogen Escherichia coli looks ...

The company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over ...

The French drugmaker said the vaccine it agreed to develop with Johnson & Johnson a year ago was “not sufficiently effective.

A comprehensive seven-year study across 20 Chinese provinces has revealed a concerning rise in antimicrobial resistance (AMR) ...

French pharma major Sanofi’s saw its shares edge up 1% by early afternoon, despite announcing a disappointment for a vaccine ...

Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical studyIndependent interim analysis of the E.mbrace phase 3 study finds that ...

Leafy greens have had a checkered past in terms of food safety — it’s been suspected that pre-harvest irrigation water may ...

Sanofi and J&J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi's Q4 2024 IFRS EPS dropped by ...

An attorney for Harris County, Texas, recently filed a lawsuit against a local utility after learning that E. coli was detected in the city waterways at 1,000 times the legal limit. Newsweek reached ...

Rand Water also emphasised that the distributed water remains safe for human consumption as it is drawn directly from the ...